The successful randomisation took place on 4th November marking a significant step forward in research for a condition with limited therapeutic options. The Oxford team’s achievement highlights their leadership in advancing treatment possibilities for patients in need.
“This has been a particularly challenging trial to set up,” said Dr Michael Fitzpatrick for the team. “It’s a new disease area with a complex protocol, and we’ve faced hurdles across contracts, equipment, pharmacy logistics, screening, and visit scheduling. The team’s dedication has been nothing short of extraordinary.”
Special recognition was given to several team members for their exceptional contributions:
- Mary, Bea, and the Pharmacy Team – for navigating the complexities of Investigational Medicinal Product (IMP) administration.
- Lekha, Ulli, and Kimg – for their tireless efforts in pre-screening patients to identify suitable candidates.
- Kimg, Chitra, and Louise – for their flexibility and commitment in coordinating patient visits.
Dr Michael Fitzpatrick added, “I’m incredibly proud that Oxford is leading the way in trials for this condition. This is a testament to the hard work, resilience, and collaboration of our entire team.”
The Sanofi MC study represents a beacon of hope for patients affected by this rare disease, and Oxford’s early success sets a strong precedent for the trial’s global rollout.
Well done to the entire team.